Reps. Watson Coleman, Veasey, Wagner and Miller-Meeks Send Letter Encouraging HHS to Expand Access to Colorectal Cancer Screenings

Reps. Watson Coleman, Veasey, Wagner and Miller-Meeks Send Letter Encouraging HHS to Expand Access to Colorectal Cancer Screenings

Reps. Bonnie Watson Coleman (NJ-12), Marc Veasey (TX-33), Ann Wagner (MO-02), and Mariannette Miller-Meeks (IA-01) sent a joint letter to Department of Health and Human Services Secretary Xavier Becerra encouraging the Department to take steps to expand access to colorectal cancer screenings.

"We are writing to urge you to ask the U.S. Preventive Services Task Force (USPSTF) to commence an expedited review and update process of its 2021 colorectal cancer screening guidelines to reflect the availability of new, innovative FDA approved non-invasive colorectal cancer tests," the Members write in their letter. "USPSTF should already have initiated its colorectal cancer screening guideline update process; however, there is no indication as to when the agency will begin this important work."

Colorectal cancer is the deadliest cancer for men under the age of 50, and the second-deadliest for women in the same age group, according to the American Cancer Society. More than 53,000 Americans are expected to die from colorectal cancer in 2024.

"Fortunately, colorectal cancer can be prevented through regular screenings, but unfortunately tens of millions of eligible Americans go unscreened often due to limited access or reluctance to undergo invasive methods including colonoscopies," write the Members.

USPSTF-recommended treatments must be covered by insurance, which significantly improves access to life-saving preventative care.

"New, innovative, and accessible screening tests are essential to increase colorectal cancer screening rates - across the eligible population - with a particular need among Americans aged 45-49 and individuals from underserved and rural communities," the letter continues. "However, due to the way the 2021 recommendation test categories were framed, without an update or amendment, these new tests fall outside the guidelines and might not be covered by insurers."

Read the full PDF of the letter here.